Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
but your right, there is always another trade or investmant lurking around the corner.
thanks for the heads up!
cheers
Walked out as well, but figured i add a few shares (half of my original investmant) for 3 month trade.
but never expected the pop too happen so soon!
thanks for alerting me to this some time back!
gl
Appreciate your questions, but you have to review the files and the websites.
I dont know everything about the company, but basics should be initiated.
lets start with the website:
I believe you answered your own question.
gl to you.
Ecyt is totally out of control today!
gl
zoraida,
i cant speak for Robert Julien. im suprised you havent asked him vetted the process, rather than assuming. I would love to know your feed back.
but your point was valid. As all three had a hand in MDGC is true.
but, some companies (OTC, amex, nasdaq, federal reserve.... etc....) dont immediately succeed, and does that equate too a scam?
we could talk about a lot of things, but why the focus on "scam" and even it was disproved by Better Business Burea- Robb Hicken (choates buddy).
gl
please reveiw the releases.
university of pennsylvania
john hopkins
cedars sinai
to name a few.
gl to you
ECYT: Long time coming.
EXTENDED HOURS:
Last: 4.15 Change: +0.430 (+11.56%) Bid: 4.02 x100 Ask: 4.15 x2,500
Q4 earnings of $-0.30 have been announced, beating analyst estimates by $0.04.
Should be an interesting open.
but was good trade, if it wwas revisted, and had some patience.
gl
Yes, and very efficient.
I have spoke to company representatives (including Meghan Feeks (media contact), James Young (IR) ,David Factor (CFO), Dr. Yu (Chief Scientific Officer-Board member), and other IR reps with ease for the past few weeks.
no explanation is needed.
gl
Its going to be interesting conference call. Hope they focus on milestones and outline the coming months.
Clarity would kickstart this company to many sideline investors.
The talent pool is impressive, but let's see how they apply it.
Cheers
would recomend everyone log on to the conference:
http://wsw.com/webcast/roth26/mdgn/
many of things mentioned in the IR CD will be mentioned in more detail.
IR could not elaborate more....
gl
It was flirted with one of the conference calls by manish singh.
its all speculation, but something thats been bantered for the past 13 months, and mentioned in passing by the ceo at one of the recent conference calls.
if anytime, this would be the best time, and this confirmed by Ayer involvement in there current interest and holdings.
another note, check out the conference:
Monday, March 14th 2012
CEO, Manish Singh will be presenting at the ROTH Conference in Dana Point - California on Wednesday, March 14, 2012 from 12pm to 12:30pm PST. Click Here to register and view the webcast.
http://www.imuc.com/webcasts-and-presentations
gl
Is 14100 our new resistance. Where do we go from their.
Dow and Nasdaq for the first time ever corss the 13000, and 3000 levels at the same time respectively!
gl
I dont think this absolute, but had discussions with few people in th epast and stated that it generally takes 8 to 12 months for OTCBB stock to uplist.
This has been speculated since january 2011.
They have been very forthright and current/transparent with there financials since than.
time will tell.
gl
GOOD AH activity:
EXTENDED HOURS:
Last: 3.83 Change: +0.110 (+2.96%) Bid: 3.75 x200 Ask: 3.83 x200
tribute to thos who held, or came back!
cheers
Endocyte Reports Fourth Quarter and Year End 2011 Financial Results and Operations UpdateFont size: A | A | A4:01 PM ET 3/13/12 | GlobeNewswire
Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced financial results for the fourth quarter and year ending Dec. 31, 2011, and provided an operational update.
"2011 was an important year in Endocyte's development, as we brought the company public and advanced our lead drug, EC145, into the Phase 3 PROCEED trial in platinum resistant ovarian cancer," said Ron Ellis, Endocyte's president and chief executive officer. "We are pleased to confirm that later this year we plan to file for conditional marketing authorization of EC145 and diagnostic imaging agent EC20, both of which have been granted orphan drug status by the European Commission, for the treatment of patients with folate-receptor positive platinum resistant ovarian cancer."
"We have made important progress in recent weeks to clarify our clinical and regulatory path forward given the continued global shortage of Doxil(R), the control drug used in the PROCEED trial," added Ron Ellis. "With the FDA's approval of our request to import our supply of Doxil, we plan to move forward with the same drug combination that yielded the compelling results in our Phase 2 PRECEDENT trial."
Upcoming Milestones
View data -- Renewed enrollment in Phase 3 PROCEED trial in early Q2 2012
-- First patient enrollment in Phase 2b/3 non-small cell lung cancer trial
in early Q2 2012
-- Submit EU marketing applications for conditional authorization of EC145
and EC20 for treatment of folate receptor positive, FR(++), platinum
resistant ovarian cancer in Q3 2012
-- Renewed enrollment in Phase 3 PROCEED trial in early Q2 2012 -- First patient enrollment in Phase 2b/3 non-small cell lung cancer trial in early Q2 2012 -- Submit EU marketing applications for conditional authorization of EC145 and EC20 for treatment of folate receptor positive, FR(++), platinum resistant ovarian cancer in Q3 2012
"Our current cash balance provides us with the financial resources to complete two important trials of EC145 and EC20 in folate-receptor positive patient populations - the Phase 3 PROCEED trial and a Phase 2b trial in second-line non small cell lung cancer. At the same time, we are in a position to bring an additional small molecule drug conjugate into the clinic," said Mike Sherman, chief financial officer of Endocyte.
Fourth Quarter Financial Results
Endocyte reported a net loss for the fourth quarter of 2011 of $10.8 million, or $0.30 per basic and diluted share, compared to $3.4 million, or $3.57 per basic and diluted share, for the same period in 2010. Weighted average common shares outstanding increased from 937,088 in the fourth quarter of 2010 to 35,745,364 in the fourth quarter of 2011 as a result of the conversion of preferred stock and the completion of the public offerings in 2011.
Revenues of $0.2 million were recognized in the fourth quarter of 2011. This revenue related to a non-refundable up-front payment associated with an exclusive worldwide license with On Target Laboratories, L.L.C. to develop and commercialize products in the field of surgical imaging. Endocyte is eligible for future royalties including minimum royalties.
Research and development expenses for the fourth quarter of 2011 were $7.8 million, compared to $3.3 million for the same period in 2010. The increase was driven by clinical and manufacturing costs related to the Phase 3 PROCEED trial and costs incurred in the preparation of the EU marketing applications for EC145 and EC20. This included process and method validations for EC20 and EC145.
General and administrative expenses for the fourth quarter of 2011 were $2.9 million, compared to $1.3 million for the same period in 2010. The increase in expenses was the result of an increase in professional fees associated with being a public company and an increase in compensation expenses.
Interest expense was $0.4 million in the fourth quarters of 2011 and 2010. The company's average debt balance was $12.9 million for the fourth quarters of 2011 and 2010.
Cash, cash equivalents and short-term investments were $128.1 million at Dec. 31, 2011, compared to $138.9 million at Sept. 30, 2011. The decrease was attributable to cash disbursements for operations.
2011 Financing Highlights
View data -- Stock offering proceeds of $144.9 million: On Feb. 9, 2011, the company
completed its initial public offering of 14,375,000 shares of common
stock. Proceeds, net of underwriting discounts, commissions and other
transaction costs were approximately $78.2 million. On Aug. 2, 2011, the
company completed a public offering of 5,839,810 shares of common stock.
Proceeds, net of underwriting discounts, commissions and other
transaction costs were approximately $66.7 million.
-- Modification to the loan arrangement with Mid-Cap Financial (Mid-Cap)
and Silicon Valley Bank (SVB): In September 2011, Endocyte modified the
loan agreement with Mid-Cap and SVB to revise the repayment terms. Under
the amendment, the interest-only period has been extended. Endocyte is
only required to make interest payments through December 2012 and then
interest and principal payments for three years beginning in January
2013. This modification provided additional working capital of $7.4
million.
-- Stock offering proceeds of $144.9 million: On Feb. 9, 2011, the company completed its initial public offering of 14,375,000 shares of common stock. Proceeds, net of underwriting discounts, commissions and other transaction costs were approximately $78.2 million. On Aug. 2, 2011, the company completed a public offering of 5,839,810 shares of common stock. Proceeds, net of underwriting discounts, commissions and other transaction costs were approximately $66.7 million. -- Modification to the loan arrangement with Mid-Cap Financial (Mid-Cap) and Silicon Valley Bank (SVB): In September 2011, Endocyte modified the loan agreement with Mid-Cap and SVB to revise the repayment terms. Under the amendment, the interest-only period has been extended. Endocyte is only required to make interest payments through December 2012 and then interest and principal payments for three years beginning in January 2013. This modification provided additional working capital of $7.4 million.
Conference Call
Endocyte management will host a conference call today at 4:30 p.m. EDT.
U.S. and Canadian participants (877) 263-3108
International (253) 237-1176
A live, listen-only webcast of the conference call may also be accessed by visiting the Investor Relations section of the Endocyte website, www.endocyte.com.
A replay of the call will be available beginning at 6:30 p.m. EDT on March 13, 2012, until midnight EDT on March 20, 2012. To access the replay, please dial (855) 859-2056 (US/Canada) or (404) 537-3406 (International) and reference the conference ID 59255581. Additionally, the webcast will be recorded and available on the company's website for two weeks following the call.
About Endocyte
Endocyte is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases. Endocyte uses its proprietary technology to create novel SMDCs and companion imaging diagnostics for personalized targeted therapies. The company's SMDCs actively target receptors that are over-expressed on diseased cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently, and over longer periods of time than would be possible with the untargeted drug alone. The companion imaging diagnostics are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment.
Forward Looking Statements
Certain of the statements made in this press release are forward looking, such as those, among others, relating to the company's expectations for seeking regulatory approval and commercial launch of its products, including any conditional marketing authorization from the EMA, initiation of future clinical trials, future availability of Doxil, data availability from ongoing and future clinical trials, and the company's expectations for its 2012 financial outlook. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include risks that the company may experience delays in the completion of its clinical trials (whether caused by competition, adverse events, patient enrollment rates, unavailability of Doxil, regulatory issues or other factors); risks that data from its clinical trials may not be indicative of subsequent clinical trial results; risks related to the safety and efficacy of the company's product candidates, the goals of its development activities, estimates of the potential markets for its product candidates, estimates of the capacity of manufacturing and other facilities required to support its product candidates, projected cash needs, and expected financial results. More information about the risks and uncertainties faced by Endocyte, Inc. is contained in the company's periodic reports filed with the Securities and Exchange Commission. Endocyte, Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
View data
Endocyte, Inc.
Statements of Operations
(in thousands, except per
share amounts)
For the Three Months For the Years
Ended December 31, Ended December 31,
2010 2011 2010 2011
----------- ----------- ---------- -----------
(unaudited) (unaudited) (unaudited)
Revenue:
License fees $ -- $ 191 $ -- $ 191
----------- ----------- ---------- -----------
Total Revenue -- 191 -- 191
Costs and expenses:
Research and development 3,290 7,753 14,561 28,828
General and
administrative 1,317 2,862 6,039 10,000
----------- ----------- ---------- -----------
Total costs and expenses 4,607 10,615 20,600 38,828
----------- ----------- ---------- -----------
Loss from operations (4,607) (10,424) (20,600) (38,637)
Interest income 2 38 8 129
Interest expense (395) (351) (1,065) (1,988)
Other income, net 1,652 (17) 1,564 (36)
----------- ----------- ---------- -----------
Net loss $ (3,348) $ (10,754) $ (20,093) $ (40,532)
=========== =========== ========== ===========
Net loss per share --
basic and diluted $ (3.57) $ (0.30) $ (21.77) $ (1.40)
=========== =========== ========== ===========
Weighted average number
of common shares used in
net loss per share --
basic and diluted 937,088 35,745,364 923,007 29,003,991
Endocyte, Inc. Statements of Operations (in thousands, except per share amounts) For the Three Months For the Years Ended December 31, Ended December 31, 2010 2011 2010 2011 ----------- ----------- ---------- ----------- (unaudited) (unaudited) (unaudited) Revenue: License fees $ -- $ 191 $ -- $ 191 ----------- ----------- ---------- ----------- Total Revenue -- 191 -- 191 Costs and expenses: Research and development 3,290 7,753 14,561 28,828 General and administrative 1,317 2,862 6,039 10,000 ----------- ----------- ---------- ----------- Total costs and expenses 4,607 10,615 20,600 38,828 ----------- ----------- ---------- ----------- Loss from operations (4,607) (10,424) (20,600) (38,637) Interest income 2 38 8 129 Interest expense (395) (351) (1,065) (1,988) Other income, net 1,652 (17) 1,564 (36) ----------- ----------- ---------- ----------- Net loss $ (3,348) $ (10,754) $ (20,093) $ (40,532) =========== =========== ========== =========== Net loss per share -- basic and diluted $ (3.57) $ (0.30) $ (21.77) $ (1.40) =========== =========== ========== =========== Weighted average number of common shares used in net loss per share -- basic and diluted 937,088 35,745,364 923,007 29,003,991
View data
Endocyte, Inc.
Balance Sheets
(in thousands, except per share amount)
As of As of
December December
31, 31,
2010 2011
-------- -----------
(unaudited)
Assets
Cash, cash equivalents and short-term
investments $ 16,873 $ 128,085
Other assets 4,341 3,590
-------- -----------
Total assets $ 21,214 $ 131,675
======== ===========
Liabilities, convertible preferred stock,
and stockholders' equity (deficit)
Current liabilities $ 7,673 $ 5,470
Long-term debt, net of current portion 11,124 12,833
Subordinated notes 9,529 --
Convertible preferred stock, no par
value 89,799 --
Total stockholders' equity (deficit) (96,911) 113,372
-------- -----------
Total liabilities, convertible preferred
stock and stockholders' equity $ 21,214 $ 131,675
======== ===========
Endocyte, Inc. Balance Sheets (in thousands, except per share amount) As of As of December December 31, 31, 2010 2011 -------- ----------- (unaudited) Assets Cash, cash equivalents and short-term investments $ 16,873 $ 128,085 Other assets 4,341 3,590 -------- ----------- Total assets $ 21,214 $ 131,675 ======== =========== Liabilities, convertible preferred stock, and stockholders' equity (deficit) Current liabilities $ 7,673 $ 5,470 Long-term debt, net of current portion 11,124 12,833 Subordinated notes 9,529 -- Convertible preferred stock, no par value 89,799 -- Total stockholders' equity (deficit) (96,911) 113,372 -------- ----------- Total liabilities, convertible preferred stock and stockholders' equity $ 21,214 $ 131,675 ======== ===========
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: Endocyte, Inc.
View dataCONTACT: Stephanie Ascher, Stern Investor Relations, Inc.
(212) 362-1200, stephanie@sternir.com
Martina Schwarzkopf, Ph.D., Russo Partners
(212) 845-4292, martina.schwarzkopf@russopartnersllc.com
Tony Russo, Ph.D., Russo Partners
(212) 845-4251, tony.russo@russopartnersllc.com
CONTACT: Stephanie Ascher, Stern Investor Relations, Inc. (212) 362-1200, stephanie@sternir.com Martina Schwarzkopf, Ph.D., Russo Partners (212) 845-4292, martina.schwarzkopf@russopartnersllc.com Tony Russo, Ph.D., Russo Partners (212) 845-4251, tony.russo@russopartnersllc.com
- EC145 and EC20 Granted Orphan Drug Status by European Commission -
- Updated Overall Survival Data Improved Compared to Interim Analysis -
WEST LAFAYETTE, Ind., March 13, 2012 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced that, per discussions with EU health authorities, the Company will submit EU conditional marketing authorization applications (MAA) for EC145 and EC20 for treatment of patients with folate-receptor positive platinum resistant ovarian cancer. The therapeutic, EC145, and the diagnostic imaging agent, EC20, have also both been granted orphan drug status by the European Commission.
"After discussions with EU health authorities about Phase 3 trial plans and updated clinical data, including an updated overall survival analysis, we are pleased to move forward with these applications," said Ron Ellis, Endocyte's president and chief executive officer. "Targeting patients with a high unmet medical need is a prerequisite to pursuing this regulatory path and, by any measure, these patients fit that definition."
Endocyte plans to file two marketing authorization applications, one application for EC145 and another for EC20, in the third quarter of 2012. This will ensure that the Phase 3 PROCEED trial enrollment is well underway. Per agreement with the EU regulators, if conditional marketing authorization is granted, data from the PROCEED trial would be submitted following authorization and PROCEED would serve as the confirmatory trial to support conversion to regular marketing authorization for EC145 and EC20.
The marketing authorization applications will be supported by four clinical studies: a Phase 1 study in solid tumors, two single-agent, single-arm Phase 2 studies in ovarian cancer and non small cell lung cancer, and the PRECEDENT trial, a randomized study in platinum-resistant ovarian cancer. The results of the PRECEDENT trial demonstrated a statistically significant delay in disease progression or death in the overall population, with the largest improvement observed in the FR(++) patient population, those with all tumors positive for the folate receptor. Women with FR(++) platinum resistant ovarian cancer who received EC145-based therapy experienced a 62 percent decrease in their risk of progression [HR 0.381, p= 0.018] compared to women receiving chemotherapy alone. Median progression free survival (PFS; the time without disease progressing) in the EC145 based treatment arm was 5.5 months compared to 1.5 months of women who received chemotherapy alone. Tumor shrinkage (overall response rate) was observed in 17.3 percent of women receiving the EC145-based therapy compared to 6.7 percent in patients treated with chemotherapy alone.
In addition, Endocyte today announced updated overall survival data from the PRECEDENT trial, which show improvement compared to the results announced in December 2011. Overall survival was a secondary endpoint in the PRECEDENT trial, but it was underpowered to demonstrate a definitive result in this endpoint. In particular, the overall survival hazard ratio for the FR(++) patient group was 1.097. Adjusting for prognostic imbalances between the study arms, the adjusted hazard ratio of 0.481 reflects a 52 percent reduction in the risk of death. Overall survival statistics in the intent-to-treat population were also slightly improved compared to those announced in December and those data will be presented at an upcoming medical conference.
"Patients with platinum-resistant ovarian cancer represent a high unmet medical need, and the presence of the folate receptor is associated with more rapid disease progression and shorter life expectancy," said Ignace B. Vergote, M.D., Ph.D., from University Hospital Leuven, in Belgium. "Because EC145 targets the folate receptor, these patients also have the potential to receive the greatest improvement over standard therapy. Being able to use EC20 to select patients who will most likely respond to the treatment will benefit both patients and doctors and is an important step towards implementing personalized medicine."
About EC145
EC145 is a conjugate of the vitamin folate and a super-potent vinca alkaloid. Folate is required for cell division and rapidly dividing cancer cells often over-express folate receptors in order to capture enough folate to support cell division. By attaching a chemotherapy drug to folate through proprietary chemistry, EC145 targets cancer cells while avoiding most normal cells. This targeted approach is designed to provide treatment with super-potent drugs while lowering toxicity compared to standard chemotherapy.
About EC20
EC20 is a folate-targeted molecular imaging agent that is being developed as a non-invasive method to identify tumors that over-express folate receptors. These tumors are the molecular target of Endocyte's folate-targeted therapeutic compounds such as EC145. To date, EC20 has been administered to over 500 patients.
About Orphan Drug Designation
EMA's Orphan Medicinal Product Designation is designed to promote the development of drugs that may provide significant benefit to patients suffering from rare, life-threatening diseases. This designation will provide ten years of marketing exclusivity if the product candidate is approved for marketing for the designated orphan indication in the European Union. It also provides special incentives for sponsors, including eligibility for protocol assistance and possible exemptions or reductions in certain regulatory fees during development or at the time of application for marketing approval.
About Endocyte
Endocyte is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases. Endocyte uses its proprietary technology to create novel SMDCs and companion imaging diagnostics for personalized targeted therapies. The company's SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently, and over longer periods of time than would be possible with the untargeted drug alone. The companion imaging diagnostics are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment.
Forward Looking Statements
Certain of the statements in this press release are forward looking, such as those, among others, relating to the enrollment of patients in clinical trials, the ability to select patients with EC20, and the acceptance of regulatory filings by regulators. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that could cause such a difference include the prolonged unavailability of Doxil, adverse regulatory developments, and the fact that clinical data from one trial may not be replicated in a subsequent trial. More information about the risks and uncertainties faced by Endocyte, Inc. is contained in the company's periodic reports filed with the Securities and Exchange Commission. Endocyte, Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: Endocyte, Inc.
View dataCONTACT: Stephanie Ascher
Stern Investor Relations, Inc.
(212) 362-1200
stephanie@sternir.com
Martina Schwarzkopf, Ph.D.
Russo Partners
(212) 845-4292
martina.schwarzkopf@russopartnersllc.com
Tony Russo, Ph.D.
Russo Partners
(212) 845-4251
tony.russo@russopartnersllc.com
CONTACT: Stephanie Ascher Stern Investor Relations, Inc. (212) 362-1200 stephanie@sternir.com Martina Schwarzkopf, Ph.D. Russo Partners (212) 845-4292 martina.schwarzkopf@russopartnersllc.com Tony Russo, Ph.D. Russo Partners (212) 845-4251 tony.russo@russopartnersllc.com
requirements:
should read these 2 articles prior to be reading the next link.
http://thestockmarketwatch.com/newsletters/2011/02/27/timelesswealth-net-imuc-to-uplist-to-amex/
http://seekingalpha.com/article/279639-uplisting-may-be-next-for-immunocellular-therapeutics
below:
http://www.amex.com/equities/howToLst/Eq_HTL_ListStandards.html
or
http://www.mondaq.com/unitedstates/x/155562/Mergers+Acquisitions/SEC+Approves+More+Rigorous+Listing+Requirements+Of+The+Major+US+Stock+Exchanges+For+Reverse+Merger+Companies
2. maintained a closing stock price of $4 (or, in the case of the NYSE Amex, either $3 or $2, depending on the applicable listing standard) per share or higher for a sustained period of time, but in no event for less than 30 of the most recent 60 trading days prior to the filing of the initial listing application and prior to listing; and
3. timely filed all required periodic financial reports with the SEC or other regulatory authority (e.g., Forms 10-Q, 10-K or 20-F), including at least one annual report containing audited financial statements for a full fiscal year commencing after filing the information described above.
gl
nice reversal past few days.
poor trend was developing.
gl
I wouldn't have known or guessed it....lol
gl mate
whats wrong with the vals bio? nothing
LOL! Everything! It's a complete fabrication. personal attack
Batteries: an intentional and obvious hoax. They didn't accidentally get lied about and re-labeled. you have a point about the labeling of the battery
g5 chip: which poster are you quoting for this one....lol
The announcement of the supposedly miraculous G5 chip came right from the company. Was in the iBox for a couple years, until a recent clean-up job by someone with a modicum of sense. Are you going to claim that MDGC never made claims about a Wytec G5 chip for phones?? Too many people remember otherwise. quoting another poster, not the company?
imperial wireless nation wide launch: which poster are you quoting again?
LOL, that's long been part of Val's ridiculous bio. You can't make these things go away by burying your head in the sand. whats wrong with his bio, and why the personal attack?
The facts are clear, MDGC is fiction. Fiction used to bamboozle investors. personal, again....
for every cagc, katx and lbsr, there are 100 failures.
even the later 2 were not sustainable due to financing issues or poor execution.
MDGC may be one of the 100, or something else........
gl
whats wrong with the vals bio?
american dream, a business man, industrial/ commercial vacum guy....who cares.
batteries: good question? is it still a probablity, maybe? but yes its an issue, and......?
g5 chip: which poster are you quoting for this one....lol
imperial wireless nation wide launch: which poster are you quoting again?
free service ( which is a smart business plan) was launched, and confirmed by choates friend....
or are you refering to the failed imperial wireless launch 3 years ago under different leadership?
one can project the perception of fact, but not necessarily the truth.
gl
thanks for the article karin.
good read.
gl
sklauble,
i have known you via ihub for many years.
i dont think MDGC is a scam, and saying it is 3000 times does not make it so.
i am critical of the execution, but time will tell!
gl to you mate!
lies from whom?
proponents?
company?
the most of the things listed on your "bucket list" seems to be a collection from posters on the board, not from the company.
not sure what your saying?
as far as i know, you could be the one touting the list.
?
gl
i could paraphrase a lot of comments from proponents and antagonists. fortunately, this a mute point. but nothing was stated by the company.
BBB is responsible for their own publishing deadline.
gl
100% agree!
investing should never be personal.
gl
Board of Directors has increased the quarterly dividend by 25% to $0.05. The next dividend is payable at the end of May.
Great for institutional stability!
gl
it is a pink sheet company, it is high risk play investmant.
if it fails , it fails like 95 percent all pinks despite the honest efforts of individuals.
but calling it a scam is disingenuous.
Its ok being critical of any company and demanding expectations, but after reviewing 3000 dedicated post twds labeling a company a scam is fairly ludicrous.
Those who are honest with themselves know how to differentiate the two, dont you think?
This is what i have a problem with. And i dont think BBB approval is going to effect the share price, nor it should.
just validate what we already know-----> its all good!
gl
MDGC is not responsible for the for BBB publishing timeline.
as this was the third time, you have brought up this point as if its MDGC fault....lol
i find that amusing, actually hilarious!
cheers
In regard to your questions-statements;
No
They never did.
Still there and involved, please call them.
Never left.
Tired? Not really. But just hanging in there.
So, what's next?
Gl to you!
Ebix will grow its quarterly earnings
Analysts believe that Ebix will post a quarterly profit of $0.41 a share, just shy of the $0.42 that the insurance-industry software provider earned a year earlier.
The pros only see a marginal dip in profitability. The other significant data point is that Ebix has landed ahead of analyst bottom-line projections for eight consecutive quarters.
Lets see what happens, but expecting a quarter ahead!
gl
No-dough,
your assesment is accurate.
Flippers build liquidity, and if public sentiment is good, the company PPS grows aswell.
if everyone holds, we are stuck....lol
gl
still involved.
apparently, things are all good with BBB
pending a few emails,....thanks choate..;)
all good!
gl
Important Question that probably will not be clarified untill, twds the end of the phase 2 results.
Since we have limited - tacitile treatment plans, unlike what we are seeing from IMUC (though its only a single arm study). it can be priceless.
current treatment modalities including gamma knife and and yearly costs range from $25,000 to $100,000 / year for each patient.
for example: Bevacizumab costs range from $30,000 to $65,000 a year/patient in various platforms in united states and england (NHS).
This is truly speculative, but propriety benefits to IMUC, and licensing treatment plans to other oncologic disease pathways is priceless can quadruple the above numbers for the company.
Im sure the company will have conference call when this are all said and done twds the end of phase 2 trials.
time will tell.
gl
This offers no beneficial investmant value unless your planning to start a cohort study.........
http://www.evaluatepharma.com/Universal/View.aspx?type=Report&id={17487AD5-A6F8-4764-98F9-A587CE69719B}¶ms=<PARAMS%20currencyId="0"><PARAM%20linkKind="0"%20compId="co_1"%20itemId="r31000027"%20/></PARAMS>&more=true#&&_ViewArgs=%7b%22_EntityType%22%3a0%2c%22_Parameters%22%3a%7b%22_ContextData%22%3a%22%7b%5c%22isEPVantage%5c%22%3afalse%2c%5c%22percentage%5c%22%3a-1%2c%5c%22searchWords%5c%22%3a%5c%22%5c%22%2c%5c%22sectionID%5c%22%3a%5c%22%5c%22%2c%5c%22storyID%5c%22%3a281060%2c%5c%22notSub%5c%22%3afalse%7d%22%7d%2c%22_Type%22%3a1%7d
Memphis Included in Analysis of Top Hypertension Hot Spots in the United States
Source Press Release
Company Takeda
Tags Cardiovascular
Date March 05, 2012
Memphis Included in Analysis of Top Hypertension Hot Spots in the United States
Commit to Control, a program challenging the 75 million Americans who have hypertension to get their high blood pressure under control, to visit Southern Women's Show
DEERFIELD, Ill., March 5, 2012 /PRNewswire/ -- A national analysis conducted by Sperling's BestPlaces and sponsored by Takeda Pharmaceuticals U.S.A., Inc., identified Memphis, Tenn., as one of the nation's Hypertension Hot Spots, or cities that have hypertension risk factors and complications. The identification of the Hypertension Hot Spots is part of a larger Takeda-sponsored hypertension awareness program called Commit to Control, which educates Americans about hypertension and also challenges patients to do all they can to get their blood pressure under control.
Memphis ranked first on the list of the 50 U.S. metropolitan areas that have hypertension risk factors and complications. Furthermore, in 2009, nearly one-third of people in the state of Tennessee had been informed they have high blood pressure, according to the Centers for Disease Control and Prevention. The large-scale Hot Spots analysis, which combined the findings of original research and existing, related research in the field of the study, analyzed data about numerous hypertension risk factors, including mortality related to hypertension – Memphis ranked first nationwide – and obesity; Memphis ranked second highest nationwide.
"Hypertension can lead to a higher risk of serious health consequences like heart attack and stroke if left uncontrolled," said Phillip Northcross, M.D., a Memphis-based internal medicine specialist. "The Hot Spots ranking reiterates hypertension's high prevalence in Memphis and reinforces the importance of patients working with their doctors to lower their blood pressure and reduce their risk for complications."
The Commit to Control exhibit will visit the Memphis Southern Women's Show on March 9-11. To motivate residents to control their high blood pressure, the exhibit will offer free blood pressure screenings and the opportunity to see the effects hypertension can have on the body through an animated 3-D simulation. The tour schedule and additional resources on how patients can take steps toward managing their hypertension are available on www.CommitToControl.com. Site visitors can also see a full list of the 50 Hypertension Hot Spots and make an online pledge to talk to their doctors about controlling hypertension. For each pledge made online, Takeda will donate $5, up to $10,000, to Mended Hearts, a community-based, nationwide heart patient support network.
About Hypertension
Hypertension, or high blood pressure, is a chronic medical condition in which the blood pressure is elevated. Blood pressure is the force of blood pushing against the walls of the arteries as the heart pumps out blood. Blood pressure numbers include systolic and diastolic pressures. Systolic pressure is the pressure exerted while the heart is beating. Diastolic blood pressure is the pressure when the heart is at rest. In blood pressure measurements, the systolic number appears above or before the diastolic number. Hypertension is defined as elevated blood pressure about 140 mm Hg or greater systolic or 90 mm Hg or greater diastolic. High blood pressure typically has no symptoms. In fact, of Americans who have hypertension, an estimated 20 percent are still unaware they have it. If left uncontrolled, hypertension can lead to serious health problems, including heart attack, stroke, kidney disease and congestive heart failure. Having high blood pressure can also shorten life expectancy by about five years, unless appropriately treated.
About the Hypertension Hot Spots Analysis
The analysis was conducted by Sperling's BestPlaces during the month of April 2011 for Takeda Pharmaceuticals U.S.A., Inc. The goal of the study was to find the metropolitan areas in the United States that have hypertension risk factors and complications. To find these places in the United States, a large-scale analysis, which combined the findings of original research and existing, related research in the field of the study, was performed. The study compiled and analyzed data for the 50 largest U.S. metropolitan areas. To determine these Hypertension Hot Spots, Sperling's BestPlaces analyzed data about the following factors: self-reported diagnoses of hypertension, self-reported diagnoses of high cholesterol, self-reported diagnoses of cardiovascular disease, doctor diagnoses of hypertension (per capita), prescriptions of hypertension-control medication (per capita), mortality relating to hypertension, average Body Mass Index (BMI), obesity rate, smoking incidence and lack of exercise. The data came from the following sources: The Centers for Disease Control and Prevention (CDC) Behavioral Risk Factor Surveillance System, The CDC Wide-ranging Online Data for Epidemiologic Research (WONDER) database, The Gallup/Healthways Well-Being poll and ESRI data derived from the Doublebase Consumer Survey performed by Mediamark Research Inc. The analysis weighed the study's categories by assigning each a magnitude of importance based upon the focus of the study; some categories offered more insight into the prevalence of hypertension. All data was adjusted by the current population to arrive at "per capita" figures to provide an accurate comparison between cities of varying sizes.
About Bert Sperling
For more than twenty years, Bert Sperling has been helping people find their own Best Places to live, work, play and retire. As the foremost creator of these studies, his work appears in the national media nearly every month. Annually, his "Healthiest Cities for Women" study is featured in SELF magazine. Other health-related projects include "Migraine Hot Spots," "Asthma Hot Spots," "Best Cities for Sleep," "America's Healthiest Cities," "Best and Worst Cities for Skin Care" and "Most Visually Inspiring Places in America." Sperling's information is available on the website, www.bestplaces.net.
Takeda Pharmaceuticals U.S.A., Inc. and Takeda Global Research & Development Center, Inc.
Based in Deerfield, Ill., Takeda Pharmaceuticals U.S.A., Inc. and Takeda Global Research & Development Center, Inc. are subsidiaries of Takeda Pharmaceutical Company Limited, the largest pharmaceutical company in Japan. The respective companies currently market oral diabetes, insomnia, rheumatology, gastroenterology, and cardiovascular treatments and seek to bring innovative products to patients through a pipeline that includes compounds in development for metabolic and cardiovascular disease, gastroenterology, neurology and other conditions. To learn more about these Takeda companies, visit www.tpna.com.
Contacts:
Jaimee Lumm
GolinHarris
312-729-4276
jlumm@golinharris.com
Jocelyn Gerst
Takeda Pharmaceuticals U.S.A., Inc.
224-554-5542
jocelyn.gerst@takeda.com
SOURCE Takeda Pharmaceuticals U.S.A., Inc.
really?
is that what means.....
lol
gl mate